Healthscope's NZ pathology business outperforms, fattening margins on tech gains, new services

Healthscope's NZ pathology business outperforms, fattening margins on tech gains, new services
Paul McBeth
By Paul McBeth Aug. 23 (BusinessDesk) - ASX-listed Healthscope's New Zealand pathology business outperformed the larger Australian divisions as an expanded offering on this side of the Tasman coincided with the roll-out of new technology to strip out costs, widening margins for the private healthcare business.  Healthscope's New Zealand unit lifted earnings before interest, tax, depreciation and amortisation 18 percent to A$59.7 million in the year ended June 30, outpacing the 3.5 percent gain across the wider group. The company anticipat...